The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying ...

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

We recently published a list of 10 AI News and Ratings You Should Not Miss. In this article, we are going to take a look at ...

Tempus AI Inc (TEM) reports impressive revenue growth, strategic acquisitions, and extended partnerships, setting the stage for a promising 2025.

Despite filing a fourth-quarter and yearend 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, ...

Tempus AI Inc (NASDAQ:TEM) shares are trading lower Tuesday after the company reported mixed fourth-quarter financial results ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in ...

Tempus AI (TEM) plunged Tuesday as its quarterly revenues missed expectations, days after insiders were reported as offloading the stock in big ...

Q4 2024 Earnings Call Transcript February 24, 2025 Tempus AI, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.15. Operator: Thank you for standing by. My name ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...